Phenothiazine-Derived Antipsychotic Drugs Inhibit Dynamin and Clathrin-Mediated Endocytosis

Traffic

Volumn 16, Issue 6, 2015, Pages 635-654

  Daniel, James A ^a,b   Chau, Ngoc ^a   Abdel Hamid, Mohammed K ^c   Hu, Lingbo ^d   von Kleist, Lisa ^e   Whiting, Ainslie ^a   Krishnan, Sai ^a   Maamary, Peter ^a   Joseph, Shannon R ^d   Simpson, Fiona ^d   Haucke, Volker ^e   McCluskey, Adam ^c   Robinson, Phillip J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antipsychotic drugs; Calmidazolium; Chlorpromazine; Drug discovery; Dynamin; Flunarizine; Fluphenazine; Phenothiazines; Small molecule inhibitors; Stemetil; Trifluoperazine

Indexed keywords

AMPHIPHYSIN; CALMIDAZOLIUM; CHLORPROMAZINE; CLATHRIN; CLOZAPINE; DROPERIDOL; DYNAMIN I; DYNAMIN II; FLUNARIZINE; FLUPHENAZINE; GUANOSINE TRIPHOSPHATASE; HALOPERIDOL; LIPID; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE; PROCHLORPERAZINE; PROMAZINE; RISPERIDONE; THIORIDAZINE; TRANSCRIPTION FACTOR AP 2; TRANSFERRIN; TRIFLUOPERAZINE; TRIFLUPROMAZINE; DYNAMIN; NEUROLEPTIC AGENT; PHENOTHIAZINE DERIVATIVE;

ARTICLE; COATED VESICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENDOCYTOSIS; ENZYME ACTIVITY; IC50; MICROSCOPY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CLATHRIN; CLATHRIN-COATED VESICLES; DYNAMINS; ENDOCYTOSIS; HUMANS; PHENOTHIAZINES; TRANSFERRIN;

EID: 84929274955     PISSN: 13989219     EISSN: 16000854     Source Type: Journal    
DOI: 10.1111/tra.12272     Document Type: Article

References (69)

1. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013;64:393-406.
2. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis -linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005;79:59-68.
3. Boyd KN, Mailman RB. Dopamine receptor signaling and current and future antipsychotic drugs. Handb Exp Pharmacol 2012;212:53-86.
4. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol 2012;212:27-52.
5. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol Biol 2008;440:15-33.
6. Scotland PB, Heath JL, Conway AE, Porter NB, Armstrong MB, Walker JA, Klebig ML, Lavau CP, Wechsler DS. The PICALM protein plays a key role in iron homeostasis and cell proliferation. PLoS One 2012;7:e44252.
7. Subtil A, Hémar A, Dautry-Varsat A. Rapid endocytosis of interleukin 2 receptors when clathrin-coated pit endocytosis is inhibited. J Cell Sci 1994;107:3461-3468.
8. Okamoto Y, Ninomiya H, Miwa S, Masaki T. Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells. J Biol Chem 2000;275:6439-6446.
9. Inal J, Miot S, Schifferli JA. The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis. Exp Cell Res 2005;310:54-65.
10. DiPaola M, Keith CH, Feldman D, Tycko B, Maxfield FR. Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. J Cell Physiol 1984;118:193-202.
11. Atwood WJ. A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy. J Neurovirol 2001;7:307-310.
12. Nawa M, Takasaki T, Yamada K, Kurane I, Akatsuka T. Interference in Japanese encephalitis virus infection of Vero cells by a cationic amphiphilic drug, chlorpromazine. J Gen Virol 2003;84:1737-1741.
13. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. HIV-1 Tat enters T-cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 2004;15:2347-2360.
14. Lecot S, Belouzard S, Dubuisson J, Rouille Y. Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis. J Virol 2005;79:10826-10829.
15. Sun X, Yau VK, Briggs BJ, Whittaker GR. Role of clathrin-mediated endocytosis during vesicular stomatitis virus entry into host cells. Virology 2005;338:53-60.
16. Bosch B, Grigorov B, Senserrich J, Clotet B, Darlix JL, Muriaux D, Este JA. A clathrin-dynamin-dependent endocytic pathway for the uptake of HIV-1 by direct T cell-T cell transmission. Antiviral Res 2008;80:185-193.
17. Rothnie A, Clarke AR, Kuzmic P, Cameron A, Smith CJ. A sequential mechanism for clathrin cage disassembly by 70-kDa heat-shock cognate protein (Hsc70) and auxilin. Proc Natl Acad Sci USA 2011;108:6927-6932.
18. Kelly BT, Owen DJ. Endocytic sorting of transmembrane protein cargo. Curr Opin Cell Biol 2011;23:404-412.
19. Wang L-H, Rothberg KG, Anderson RG. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J Cell Biol 1993;123:1107-1117.
20. Hunt RC, Marshall-Carlson L. Internalization and recycling of transferrin and its receptor. Effect of trifluoperazine on recycling in human erythroleukemic cells. J Biol Chem 1986;261:3681-3686.
21. Umasankar PK, Sanker S, Thieman JR, Chakraborty S, Wendland B, Tsang M, Traub LM. Distinct and separable activities of the endocytic clathrin-coat components Fcho1/2 and AP-2 in developmental patterning. Nat Cell Biol 2012;14:488-501.
22. Martin KJ, Arthur JS. Selective kinase inhibitors as tools for neuroscience research. Neuropharmacology 2012;63:1227-1237.
23. Vickery RG, Von Zastrow M. Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol 1999;144:31-43.
24. Schrier SL, Chiu DT, Yee M, Sizer K, Lubin B. Alteration of membrane phospholipid bilayer organization in human erythrocytes during drug-induced endocytosis. J Clin Invest 1983;72:1698-1705.
25. Sengupta P, Ruano MJ, Tebar F, Golebiewska U, Zaitseva I, Enrich C, McLaughlin S, Villalobo A. Membrane-permeable calmodulin inhibitors (e.g. W-7/W-13) bind to membranes, changing the electrostatic surface potential: dual effect of W-13 on epidermal growth factor receptor activation. J Biol Chem 2007;282:8474-8486.
26. Harper CB, Popoff MR, McCluskey A, Robinson PJ, Meunier FA. Targeting membrane trafficking in infection prophylaxis: dynamin inhibitors. Trends Cell Biol 2013;23:90-101.
27. Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell LR, Chau N, Quan A, Mariana A, Sakoff JA, Chircop M, Robinson PJ, McCluskey A. Inhibition of dynamin mediated endocytosis by the dynoles™ - synthesis and functional activity of a family of indoles. J Med Chem 2009;52:3762-3773.
28. Robertson MJ, Deane FM, Robinson PJ, McCluskey A. Synthesis of Dynole 34-2, Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase. Nat Protoc 2014;9:851-870.
29. Harper CB, Martin S, Nguyen TH, Daniels SJ, Lavidis NA, Popoff MR, Hadzic G, Mariana A, Chau N, McCluskey A, Robinson PJ, Meunier FA. Dynamin inhibition blocks botulinum neurotoxin type-A endocytosis in neurons and delays botulism. J Biol Chem 2011;286:35966-35976.
30. McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, Whiting A, Gorgani N, Lloyd J, Quan A, Moshkanbaryans L, Krishnan S, Perera S, Chircop M, von Kleist L, et al. Building a better dynasore: the dyngo™ compounds potently inhibit dynamin and endocytosis. Traffic 2013;14:1272-1289.
31. McGeachie AB, Odell LR, Quan A, Daniel JA, Chau N, Hill TA, Gorgani NN, Keating DJ, Cousin MA, van Dam EM, Mariana A, Whiting AE, Perera S, Novelle AE, Young KA, et al. Pyrimidyn™ compounds: dual-action small molecule pyrimidine-based dynamin inhibitors. ACS Chem Biol 2013;8:1507-1518.
32. Odell LR, Howan D, Gordon CP, Robertson MJ, Chau N, Mariana A, Whiting AE, Abagyan R, Daniel JA, Gorgani NN, Robinson PJ, McCluskey A. The pthaladyns™: GTP competitive inhibitors of dynamin I and II GTPase derived from virtual screening. J Med Chem 2010;53:5267-5280.
33. Hill TA, Mariana A, Gordon CP, Odell LR, McGeachie AB, Chau N, Daniel JA, Gorgani NN, Robinson PJ, McCluskey A. Iminochromene inhibitors of dynamin I & II GTPase activity and endocytosis. J Med Chem 2010;53:4094-4102.
34. Robertson MJ, Hadzic G, Ambrus J, Hyde E, Yuri Pomè D, Chau N, Whiting AE, Robinson PJ, McCluskey A. The Rhodadyn™ series, a new class of small molecule inhibitors of dynamin GTPase activity. ACS Med Chem Lett 2012;3:352-356.
35. Hill TA, Odell LR, Quan A, Abagyan R, Ferguson G, Robinson PJ, McCluskey A. Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity. Bioorg Med Chem Lett 2004;14:3275-3278.
36. Zhang J, Lawrance GA, Chau N, Robinson PJ, McCluskey A. From Spanish fly to room temperature ionic liquids (RTILs): synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs. New J Chem 2008;32:28-36.
37. Quan A, McGeachie AB, Keating DJ, van Dam EM, Rusak J, Chau N, Malladi CS, Chen C, McCluskey A, Cousin MA, Robinson PJ. MiTMAB is a surface-active dynamin inhibitor that blocks endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol 2007;72:1425-1439.
38. Soulet F, Yarar D, Leonard M, Schmid SL. SNX9 regulates dynamin assembly and is required for efficient clathrin-mediated endocytosis. Mol Biol Cell 2005;16:2056-2067.
39. Knezevic I, Predescu D, Bardita C, Wang M, Sharma T, Keith B, Neamu R, Malik AB, Predescu S. Regulation of dynamin-2 assembly-disassembly and function through the SH3A domain of intersectin-1s. J Cell Mol Med 2011;15:2364-2376.
40. Wu XS, McNeil BD, Xu J, Fan J, Xue L, Melicoff E, Adachi R, Bai L, Wu LG. Ca(2+) and calmodulin initiate all forms of endocytosis during depolarization at a nerve terminal. Nat Neurosci 2009;12:1003-1010.
41. Thomas PG, Seelig J. Binding of the calcium antagonist flunarizine to phosphatidylcholine bilayers: charge effects and thermodynamics. Biochem J 1993;291(Pt 2):397-402.
42. Lara B, Gandia L, Torres A, Olivares R, Martinez-Sierra R, Garcia AG, Lopez MG. 'Wide-spectrum Ca2+ channel antagonists': lipophilicity, inhibition, and recovery of secretion in chromaffin cells. Eur J Pharmacol 1997;325:109-119.
43. Villarroya M, Gandia L, Lara B, Albillos A, Lopez MG, Garcia AG. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells. Br J Pharmacol 1995;114:369-376.
44. von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, MacGregor KA, Tomilin N, Pechstein A, Chau N, Chircop M, Sakoff J, von Kreis J, Saenger W, Krausslich HG, et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 2011;146:471-484.
45. Maritzen T, Schmidt MR, Kukhtina V, Higman VA, Strauss H, Volkmer R, Oschkinat H, Dotti CG, Haucke V. A novel subtype of AP-1-binding motif within the palmitoylated trans-Golgi network/endosomal accessory protein Gadkin/gamma-BAR. J Biol Chem 2010;285:4074-4086.
46. Huang B, Bates M, Zhuang X. Super-resolution fluorescence microscopy. Annu Rev Biochem 2009;78:993-1016.
47. Ramachandran R, Pucadyil TJ, Liu YW, Acharya S, Leonard M, Lukiyanchuk V, Schmid SL. Membrane insertion of the pleckstrin homology domain variable loop 1 is critical for dynamin-catalyzed vesicle scission. Mol Biol Cell 2009;20:4630-4639.
48. Shnyrova AV, Bashkirov PV, Akimov SA, Pucadyil TJ, Zimmerberg J, Schmid SL, Frolov VA. Geometric catalysis of membrane fission driven by flexible dynamin rings. Science 2013;339:1433-1436.
49. Leterrier FR, Rieger F, Mariaud JF. Comparative studies of synaptic membrane protein solubilization by chlorpromazine and sodium dodecylsulfate. Biochem Pharmacol 1974;23:103-113.
50. Brett TJ, Traub LM, Fremont DH. Accessory protein recruitment motifs in clathrin-mediated endocytosis. Structure (Camb) 2002;10:797-809.
51. Taylor MJ, Perrais D, Merrifield CJ. A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis. PLoS Biol 2011;9:e1000604.
52. Loerke D, Mettlen M, Yarar D, Jaqaman K, Jaqaman H, Danuser G, Schmid SL. Cargo and dynamin regulate clathrin-coated pit maturation. PLoS Biol 2009;7:e57.
53. Ferguson SM, Raimondi A, Paradise S, Shen H, Mesaki K, Ferguson A, Destaing O, Ko G, Takasaki J, Cremona O, O' Toole E, De Camilli P. Coordinated actions of actin and BAR proteins upstream of dynamin at endocytic clathrin-coated pits. Dev Cell 2009;17:811-822.
54. Aguet F, Antonescu CN, Mettlen M, Schmid SL, Danuser G. Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint. Dev Cell 2013;26:279-291.
55. Otomo M, Takahashi K, Miyoshi H, Osada K, Nakashima H, Yamaguchi N. Some selective serotonin reuptake inhibitors inhibit dynamin I guanosine triphosphatase (GTPase). Biol Pharm Bull 2008;31:1489-1495.
56. Takahashi K, Miyoshi H, Otomo M, Osada K, Yamaguchi N, Nakashima H. Suppression of dynamin GTPase activity by sertraline leads to inhibition of dynamin-dependent endocytosis. Biochem Biophys Res Commun 2010;391:382-387.
57. Gietzen K, Wuthrich A, Bader H. R 24571: a new powerful inhibitor of red blood cell Ca++-transport ATPase and of calmodulin-regulated functions. Biochem Biophys Res Commun 1981;101:418-425.
58. Rosa JM, Conde M, Nanclares C, Orozco A, Colmena I, de Pascual R, Garcia AG, Gandia L. Paradoxical facilitation of exocytosis by inhibition of L-type calcium channels of bovine chromaffin cells. Biochem Biophys Res Commun 2011;410:307-311.
59. Thakur A, Sahai AK, Thakur JS. Experimental re-evaluation of flunarizine as add-on antiepileptic therapy. J Pharm Bioallied Sci 2011;3:253-258.
60. Hasan M, Pulman J, Marson AG. Calcium antagonists as an add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev 2013;3:CD002750.
61. Kuromi H, Honda A, Kidokoro Y. Ca(2+) influx through distinct routes controls exocytosis and endocytosis at Drosophila presynaptic terminals. Neuron 2004;41:101-111.
62. Schubert KO, Focking M, Prehn JH, Cotter DR. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder? Mol Psychiatry 2011;17:669-681.
63. Focking M, Dicker P, English JA, Schubert KO, Dunn MJ, Cotter DR. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Arch Gen Psychiatry 2011;68:477-488.
64. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004;9:684-697.
65. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 2006;11:459-570.
66. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, Wait R, Dunn MJ, Cotter DR. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 2008;13:1102-1117.
67. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyas E, Eberlin MN, Souza GH, Marangoni S, Novello JC, Turck CW, Dias-Neto E. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 2009;43:978-986.
68. Quan A, Robinson PJ. Rapid purification of native dynamin I and colorimetric GTPase assay. Methods Enzymol 2005;404(Ch 49):556-569.
69. Labute P, Williams C, Feher M, Sourial E, Schmidt JM. Flexible alignment of small molecules. J Med Chem 2001;44:1483-1490.